|
At the show, BioPlus unveiled its HUGRO Shine+AURA skin regeneration solution and newly launched Hair Solution line, both based on the company’s proprietary recombinant growth factor technology. HUGRO, short for Human Growth Factor Recombination Technology, utilizes key bioactive peptides such as EGF, FGF, and TGF to activate cell regeneration and restore skin and scalp health at a fundamental level.
Starting on day one, the products attracted strong interest from dermatologists and plastic surgeons across the U.S. “The regeneration effect is fast and post-treatment irritation is minimal,” commented one medical professional after testing the product. The Hair Solution line, designed to improve alleviate scalp concerns such as dryness or irritation and strengthen hair follicles, also drew praise from hair loss clinics for its efficacy and innovation.
This year’s TAS exhibition was particularly meaningful for BioPlus as it marked the official U.S. launch of its HUGRO platform following its certification under the Modernization of Cosmetics Regulation Act (MoCRA), a key validation of product safety and quality required for entry into the American market. The certification reinforced the credibility of the technology and helped accelerate meaningful discussions with local distributors and medical institutions.
A company representative stated, “The overwhelmingly positive response from global professionals, despite it being our first appearance at TAS, clearly reflects how well HUGRO aligns with current market demands and industry trends. We see this exhibition as a strategic springboard to solidify our global presence, particularly in the U.S. aesthetic and medical skincare markets.”
With innovation at its core, BioPlus is poised to expand its global footprint by delivering regenerative solutions that go beyond surface-level beauty and revitalize skin health at the cellular level.
Copyright ⓒ 이데일리 무단 전재 및 재배포 금지
본 콘텐츠는 뉴스픽 파트너스에서 공유된 콘텐츠입니다.
다음 내용이 궁금하다면?
광고 보고 계속 읽기
원치 않을 경우 뒤로가기를 눌러주세요
